Fifty-nine neonates with herpes simplex virus (HSV) infection were evaluated with use of assays for neutralizing antibody (NAb), lymphocyte transformation (LT), a interferon production, and virus-specific antibody (immunoblots). Infants with disseminated disease or onset in the first week of life were more likely to lack NAb. Patients treated with vidarabine were more likely than those treated with acyclovir to develop a fourfold rise in NAb titer. Infants with encephalitis showed a broader spectrum of IgG and IgM antibody reactivity against HSV proteins by immunoblotting than did those who had earlier onset of mucocutaneous illness. Only 10 of 33 infants had HSV-specific LT, compared with eight of eight adults with primary HSV. Neonates with positive LT were more likely to show a fourfold rise in NAb titer. In vitro a interferon production was diminished in infants, compared with values in adults.
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Most neonates who develop herpes simplex virus (HSV) infection do not localize viral replication to mucocutaneous sites. The age-related susceptibility to severe HSV is presumed to result from deficiencies of the neonatal host response to this viral infection. Data concerning HSV-specific immunity in relation to HSV pathogenesis in the human newborn are limited [1, 2] . The analysis of the immune response in these infants is of more than theoretical interest. Current antiviral therapy improves the outcome of neonatal HSV infection, but the death rate among infants who have disseminated disease re-mains 40070, and f\.J75OJo of the survivors of CNS infection have sequelae [3] . New strategies for the prevention and treatment of neonatal HSV infection may result from a better understanding of the neonatal immune response to HSV.
Subjects and Methods
Patient population. Fifty-nine infants with HSV infections were evaluated between July 1976 and October 1985. HSV was isolated from each patient. The ages at onset of illness ranged from one day to eight weeks. The infants were classified as preterm if the gestation was <37 weeks. Mucocutaneous HSV infection was defined as disease limited to the skin, eyes, or mucous membranes; these infants had normal hematologic, liver, and renal function tests and normal CSF. Disseminated HSV infection denoted disease with visceral involvement, usually of the liver, lungs, or both, with or without associated mucocutaneous or CNS infection. Infants with encephalitis (regardless of whether or not they had mucocutaneous infection) had intractable seizures, elevated cell counts and protein content in CSF, and abnormalities that appeared on serial computerized tomographic scans. The diagnosis of encephalitis was made by brain biopsy in infants without mucocutaneous lesions at initial presentation. Congenital (intrauterine) HSV infection was diagnosed by the presence of skin lesions at or near birth and by microcephaly, with or without chorioretinitis. Some infants were diagnosed before antiviral therapy was available. Subsequently, infants with HSV infection were enrolled in the randomized trials of vidarabine and acyclovir (ACV) conducted by the National Institute of Allergy and Infectious Diseases (Bethesda, Md). Vidarabine was given at a dosage of 15 or 30 mg/kg per day and ACV at 30 mg/kg per day. If parents preferred not to participate in the randomized studies, most infants received ACV. Healthy, nonpregnant, adult women with primary HSV infection were evaluated for comparison with the neonates. These women did not have detectable neutralizing antibody (NAb) to HSV at the time of appearance of their first clinical lesions.
Laboratory methods. NAb to HSV. NAb titers were measured by microneutralization assay with sera stored at -20 C [4] . Serial dilutions of serum (0.025 ml) were incubated with an equal volume of 100 TCID so of HSV type 1 (HSV-l; strain MacIntyre, ATCC VR 539) or type 2 (HSV-2; strain MS, VR 540) in replicates of six at 37 C for 1 hr. The same pools of HSV-l and HSV-2 were used throughout the study. Human foreskin fibroblasts (200,000 cells/ml) were added to each well in a volume of 0.05 m!. When the back titration read 100 TCID so ± 0.5 log, each well was scored for CPE. The 50070 end point for the six replicates was calculated by the Karber method.
Culture and typing of HSV isolates. Samples were inoculated onto monolayers of human foreskin fibroblasts and observed for CPE. HSV typing was done by direct fluorescent-antibody staining with type-specific monoclonal antibodies (Syva, Palo Alto, Calif) or by restriction endonuclease analysis [4] .
Lymphocyte transformation. Peripheral blood mononuclear cells were separated by FicollHypaque® (Pharmacia, Piscataway, NJ) gradients and cultured in McCoy's medium and 30070 human sera. Cells (3 x 105 cells per well) were incubated with inactivated HSV-l (strain Macintyre, ATCC VR 539)-and HSV-2 (strain MS, VR 540)-infected cell antigens and an uninfected cell control. Cultures were pulsed with [3H]thymidine after four days and harvested onto filter paper on day 5. Thymidine incorporation was measured with a liquid scintillation counter. T lymphocyte proliferation in response to HSV was considered present if a threefold increase in cpm in the antigen-stimulated wells was detected when compared with the control wells [5] .
Interferon (IFN) production. In vitro IFN-a production was measured after the supernatants were harvested from microtiter wells containing periph-29 eral blood mononuclear cells that had been incubated with inactivated HSV-l or HSV-2 antigen for five days. Serial threefold dilutions of the supernatants were tested in a microtiter assay [5] with vesicular stomatitis virus, which has been shown to detect IFN-a but not IFN-y [6] , as the challenge virus.
Immunoblot procedure. HSV-l-and HSV-2-infected cell proteins were prepared from confluent HEp-2 cells infected with HSV-l (strain MacIntyre, ATCC VR 539) or HSV-2 (strain MS, VR 540), respectively, at 5 pfu per cell and incubated for 72 hr [7] . A sonicated preparation of infected cells was solubilized with 0.5070 Triton X-l00 and 0.1070 SDS and ultracentrifuged. Supernatant samples were mixed 1:1 with a disruption buffer (0.056 M Tris-HCI [pH 6.8], 1070 SDS, 1070 2-mercaptoethanol, and 1070 glycerol), heated at 100 C for 90 sec, and stored at -70 C. Electrophoresis was done with a 9070 SDSpolyacrylamide gel cross-linked with N,N 1 - methylene-bisacrylamide at a ratio of 30:0.8 [8] . All gels contained 0.1 070 SDS, 0.075070 ammonium persulfate, and 0.050/0 N,N,Nt,N-tetramethylethylenediamine. Cell extract preparations were added to wells and electrophoresed at a constant current of 20 rnA at room temperature ( rv 23 C) for rv8 hr. Electrophoresed proteins were transferred to nitrocellulose with a Trans-Blot® chamber (BioRad, Richmond, Calif) after resolving gels and nitrocellulose sheets were equilibrated in blotting buffer (0.025 M Tris and 0.192 M glycine in 20070 methanol) for 30 min [9] . Transfer was done at 4 C for 16 hr with use of a constant 30-V power source. After transfer the nitrocellulose sheets were rinsed for 30 min in PBS (pH 7.5), covered with clear plastic wrap, and frozen at -20 C. Protein standards were stained with India ink [10] . After incubation in T-PBS (0.05070 Tween-20 in 10 mM dibasic sodium phosphate and 0.9070 NaCI, pH 7.5) for 30 min, a strip with infected cell proteins of the infecting type of virus (HSV-l or HSV-2) was immersed for 1 hr in the test serum, which had been diluted 1:50 with T-PBS. Each strip was washed in T-PBS and then incubated with biotinylated goat antibody to human IgG or IgM and an avidin-biotin complex (ABC) solution with use of the Vectastain® ABC. Kit (Vector Laboratories, Burlingame, Calif). Substrate (0.05070 4-chloro-lnaphthol, 0.0125070 H 2 0 2 , and 16% methanol in PBS) was added for 15 min of incubation in the dark. The immunoperoxidase reaction was terminated by a water rinse.
Molecular weights were estimated with use of cu-bic spline interpolation [11] and a personal computer program for the IBM-PC/XT® developed by Allen R. Curran (Department of Mechanical Engineering, Stanford University, Stanford, Calif).
Statistics.
Fisher's test of exact probability (twotailed) was used, except that student's t test was used in the comparison of IFN titers, as noted in the text [12] . Values of P > .05 were considered not significant. When multiple analyses were done from a single data set, a P value of < .01 should be considered more reliable than P < .05, which is only suggestive.
Results
Clinical characteristics of the patient population. Fifty-five infants had perinatally acquired HSV infection (table 1) and four infants had intrauterine infection. Sixteen (29070) of the perinatal infections were with HSV-l, and 39 (71070) were with HSV-2. Twenty infants (36070) had mucocutaneous infection; 15 had disseminated disease (27070), including 6 with dissemination and encephalitis; and 20 had encephalitis (36070). Thirty infants (54070) received ACV therapy, 17 (31 %) received vidarabine, and 8 (15070) were not treated. Four adults had HSV-l and four had HSV-2 mucocutaneous infections. None received antiviral therapy.
A high proportion of infants with perinatal HSV was preterm (15 [270/0] of 55). Disseminated disease (six cases) and mucocutaneous HSV (nine cases) were significantly more common than encephalitis (no cases) in preterm infants (both P < .02).
An analysis by type of virus showed that infants infected with HSV-l had either mucocutaneous HSV (11 [69070] was isolated from all of the infants with intrauterine HSV infection.
An analysis by age at onset showed that 10 (43070) of 23 patients with symptoms at one to seven days were infected with HSV-l and 13 (57070) with HSV-2. Six (35070) of 17 patients with onset at eight to 14 days had HSV-l, and 11 (65070) had HSV-2. Fifteen infants had onset of symptoms at 15 days to eight weeks of age, including three with onset after four weeks of age. All of these infants were infected with HSV-2, and 13 of these 15 infants had encephalitis. The two preterm infants in this late-onset group had mucocutaneous HSV-2 infection. Patients with onset at one to seven days were more likely to be infected with HSV-l than were those with onset after 15 days of age (10 of 23 vs. none of 15; P = .0048). Encephalitis was less common in the group with onset at one to seven days of age than in the group with onset after 15 days (13 of Infants with disseminated HSV infection were more likely to lack detectable NAb in week 1 (eight [73<%] of 11) than were patients with encephalitis (two [11%] of 19; P< .01). Six (35070) of 17 infants with mucocutaneous disease lacked NAb in week 1, a result not significantly different from that for the encephalitis or disseminated disease groups (table 2). Table 1 . Clinical, virological, and treatment characteristics of patients with perinatally acquired HSV infection. The range of NAb titers during weeks 1 and 2 was similar for ACV and vidarabine recipients and untreated patients. In weeks 3-4, a significant difference was seen, with eight of 10 vidarabine recipients having NAb titers of >1 :20 compared with three of 19 ACV recipients (P < .003). This difference persisted when only the term infants in these two groups were compared (six of seven vs. two of 13; P < .01).
Immunoblot analysis ofIgG and IgM antibodies
Only one of 26 ACV recipients developed a fourfold rise in NAb titer, compared with six of 12 vidarabine recipients (P < .005). This difference also persisted after preterm infants were excluded (none of 17 vs. five of nine; P < .005).
A fourfold rise in NAb titer was seen in eight of 42 neonates. Infants whose NAb titer was <1 :5 during the first week were as likely to have a fourfold rise in NAb titer (one of 12) as were those whose initial titer was~1:5 (seven of 30). Four (80%) of five infants who had a fourfold rise in NAb titer also had a lymphocyte transformation index (TI) of~3.0. to homologous HSV antigens. The most prominent IgG and IgM antibody reactivity in sera from infants with HSV was directed against HSV-infected cell proteins of 130-160, 80, and 38-46 kDa (figure 2). IgG antibodies were detected against a broader spectrum of both HSV-1-and HSV-2-infected cell proteins, compared with IgM antibodies. Nevertheless, some infants showed IgG antibodies to only a few HSV proteins when they were tested during or after the second week of illness (figure 2, left; sera 3,4, 8, 18, and 20). A comparison of immunoblots according to age at onset showed that the group with onset at one to seven days had absent or poorly defined IgG reactivity more often than did the later-onset group. The early-onset group differed from the later-onset group in that more infants in the former were preterm (four of 13 vs. none of seven), had mucocutaneous disease (eight of 13 vs. none of seven), and had HSV-l infection (five of 13 vs. none of seven).
Two (20) infected cell proteins by immunoblotting (figure 2; sera 6 and 7). IgM antibody production byinfants with HSV was not detectable in sera from two infants who were tested <10 days after onset of symptoms (figure 2, bottom; sera 1 and 7). IgM antibody to HSV proteins was present in three of six infants tested at 10, 11, and 12 days and in 13 of 17 infants tested more than two weeks after onset. The IgM response ofpatients infected with HSV-1 was undetectable (figure 2, right; sera 1-3, 6, 17, and 18) or diminished (figure 2, right; sera 4, 5, and 19) compared with patients infected with HSV-2. Other variables associated with this difference were that eight of 11 infants infected with HSV-l had mucocutaneous HSV infection and that all had onset of symptoms in the first two weeks of life. IgM antibody was present in nine of 10 infants with encephalitis, compared with only two of 11 infants with mucocutaneous HSV infection. The 10 infants with encephalitis were infected with HSV-2, and seven had become ill after two weeks of age.
The patterns of IgG and IgM antibody reactivity to HSV antigens in sera from patients infected with HSV-2 were similar for ACV and vidarabine recipients (figure 2). IgG and IgM binding was diminished in infants infected with HSV-l who were treated with ACV ( figure 2, sera 1~6 ). This group included only patients with mucocutaneous disease; three were preterm infants, and all had symptoms within the first two weeks of life.
In vitro lymphocyte transformation in response to homologous HSVantigen. Only 10 (30070) of 33 infants who were tested for lymphocyte transformation in response to HSV within two to four weeks after the onset of symptoms had a TI of~3.0, compared with eight (100070) of eight adults with primary HSV infection (P = .001; table 3 and figure 3 ). The number of patients with a TI of~3.0 was significantly lower for preterm (none of five; P < .002) and term (10 of 28; P < .003) infants compared with adults and for preterm compared with term infants (P < .03). Four of 12 infants infected with HSV-1 had a TI of~3.0, compared with seven of 21 infants infected with HSV-2. Infants with encephalitis had a TI of~3.0 (six [43070] of 14) more often than did infants with mucocutaneous HSV (one [11070] of nine) or disseminated HSV (three [30070] of 10) infection, but these differences were not statistically significant. Infants who were in the older age group (15 days to eight weeks) at onset were more likely nates and five of six <;ldults during the first four weeks after onset of infection(P = .0780).
Immunity to HSV in infants with recurrent clinical symptoms in the first two months after the initial HSV infection. Twelve infants had recurrent HSV infection within two months after onset of the initial illness. Ten of these infants had recurrent cutaneous lesions, but two infants developed encephalitis after treatment of mucocutaneous HSV infection. Two of these infants were treated with vidarabine for the initial infection, and 10 received ACV, including the two infants who developed encephalitis. Four patients had HSV-1 and eight had HSV-2 infection. Eight of the infants were term, and four were preterm. Two infants had multiple cutaneous recurrences within the first two months.
Sequential antibody levels were determined in 11 infants during the first month after onset of the initial infection. Ten had NAb titers of >1:5 by two to four weeks after onset of the initial symptoms. Four infants (33 %) had cutaneous recurrences despite NAb titers of >1:20. Two infants (18070) showed a fourfold rise in antibody titer. The HSV TI was~3.0 in one (17070) of six infants with recurrent HSV who had been tested after treatment of the initial infection.
The two infants who later developed encephalitis had no detectable NAb at the time of the initial mucocutaneous HSV-2 infection. Both infants had NAb titers of <1 :5 when encephalitic symptoms occurred at three and six weeks of age, respectively. One infant was term, and the other was preterm. The preterm infant had an HSV TI of 2.8 at three to four weeks after the initial illness; the value was again 2.8 at 12 days after onset of encephalitis. In vitro IFNa production in response to HSV antigen was detected (log IFN titer, 1.43) after the initial illness and before the occurrence of encephalitis.
The IgG and IgM immunoblots of four patients with recurrent HSV are shown in figure 2 (sera 10,  16,22, and 25 ). Serum 16 shows the immunoblot of the term infant who had cutaneous HSV followed by encephalitis. No IgG or IgM reactivity to HSV proteins was detected; this result correlated with the absence of NAb in this infant.
Immunity to HSV in infants with intrauterine infection. Four neonates with HSV infections acquired in utero were evaluated. Two were term, and two were preterm, born at 35 and 36 weeks of gestation. Cutaneous HSV lesions were present at birth in three infants and appeared on day 3 in one. All~l
. to develop lymphocyte proliferation in response to HSV (six of nine) than were infants with onset of symptoms at one to seven days (one of 13; P< .02). Two of 14 ACV recipients developed a TI of~3.0, compared with seven of 14 infants given vidarabine (P = .1032) and one of five infants who received no therapy. A fourfold rise in NAb titer was seen in four (50%) of eight patients with a TI of~3.0 but in only one (5.9070) of 17 of those with a TI of <3.0 (P = .0448).
In vitro IFN-a production. In vitro IFN-a production was evaluated in 11 neonates and eight adults. The neonates included nine term and two preterm infants; six had encephalitis, two had disseminated HSV infection, and three had mucocutaneous disease. Two infants had HSV-1 and nine had HSV-2 infection. Six infants received ACV, two received vidarabine, and three were not treated. The mean ± SD log IFN-a titers within two weeks after onset were 0.75 ± 0.69 for neonates and 1.09 ± 0.83 for adults. Three (27070) of 11 neonates had log IFN titers of 1.0 compared with three (43070) of seven adults. During weeks 3 and 4 after onset, the mean ± SD log IFN titers were 0.63 ± 0.55 for neonates and 1.81 ± 0.72 for adults (P< .005 by Student's ttest). Two (25070) of eight neonates had log IFN titers of~1.0 compared with six (86070) of seven adults. A rise in in vitro IFN-a production was seen in one of six neo-infants were microcephalic, two were small for gestational age, and three had chorioretinitis. The NAb titers at one to eight days of life were ;;?;1:45 in all four infants. The HSV TI was ;;?;3.0 in the first four weeks of life in all four patients. All of these infants had multiple cutaneous recurrences in the first year of life.
Discussion
Transplacentally acquired NAb to HSV may protect many infants from HSV infection despite exposure to the virus at delivery or in the first few days of life [4] . Passive antibody administration provides protection in animal models of HSV infection [1] . Once an infant has become infected with HSV, the presence or absence of transplacentally acquired antibody might be expected to modify the pathogenesis of the infection. In this study, infants with symptoms of HSV infection within the first week of life were more likely to lack NAb to HSV. Infants with disseminated infection were also more likely to lack NAb. Most infants who developed symptoms later had NAb titers of >1:5 and localized infection. Unfortunately, many of these infants had encephalitis, so that the potential modification of infection by NAb did not protect against a devastating clinical illness. The pathogenesis of HSV encephalitis in some infants may resemble that of HSV-l encephalitis in the older child and adult, a disease that occurs despite preexisting NAb [13] .
The severity of the clinical illness caused by HSV in infants has been attributed to deficiencies in the neonatal immune response. The assessment of production of IgG antibody to HSV by infected infants is complicated by the presence of maternal antibodies. However, 19010 of infants had a fourfold rise in NAb titer in the first four weeks after onset of HSV symptoms, a finding comparable to the NAb response of adults with primary HSV. The analysis of production of IgM antibody to HSV by the immunoblot technique indicated that early IgM antibody synthesis was not prominent in the immune response of infants with HSV. Infants with HSV encephalitis had evidence of production of IgM antibody to a broader spectrum of HSV proteins by. immunoblot than did other infants. These infants were older at onset, a factor that allowed for a longer incubation period with opportunity for antigenic stimulation or for possible maturation of the immune system. More-extensive tissue infection with 35 HSV encephalitis might also produce greater antigenic stimulation of the host response. A difference in the immunogenicity of HSV-2 compared with HSV-l does not seem to be a likely explanation, because the NAb and immunoblot antibody responses of infants who were younger at onset or who had mucocutaneous or disseminated disease did not differ between infants infected with HSV-l or HSV-2.
Cellular immunity has been considered to be an important host reponse in primary herpesvirus infections. By comparison with adults, infants studied during the first four weeks after primary HSV-l and HSV-2 infections showed markedly diminished T lymphocyte proliferation in response to HSV. Most infants had no detectable T lymphocyte response to HSV at two to four weeks after onset of symptoms. More-severe primary HSV in adults has been correlated with a prolonged time to acquisition of the T lympyocyte proliferation response to HSV [14] . Whether the response to HSV was specifically impaired or occurred because of a generalized supression of T lymphocyte proliferation could not be determined because these infants had not been exposed to other T lymphocyte-dependent antigens. Burchett et al. [15] detected a lymphocyte proliferation in response to HSV in four of 10 samples from HSVinfected neonates tested during the first month of life, and Pass et al. [16] found that only three of six infants who had had neonatal HSV-2 infection had lymphocyte proliferation in response to HSV in the first six months of life. Cord blood mononuclear cells from uninfected neonates process and present HSV antigen, but the responder cell frequency is very low [17] . Diminished proliferation in response to HSV was associated with a decrease in T lymphocyte responder cell frequency among infants after neonatal HSV infection (A. Hayward, P. Liebson, and A.M.A., unpublished observation). That only one of nine infants with mucocutaneous HSV infection developed T lymphocytes that responded to HSV antigens may explain the clinical observation that 75010 of these infants progress to life-threatening HSV infection if not treated early [18] . The failure of many infants to develop cellular immunity to HSV as late as four weeks after the initial clinical symptoms may allow serious recurrent HSV. The two infants in this study who developed encephalitis after early treatment for mucocutaneous HSV disease had limited HSV-specific immunity at the time of onset of encephalitis.
Although leukocytes from uninfected neonates are able to respond to HSV stimulation in vitro with IFN-a production similar to that of adults [19, 20] , in vitro IFN-a production in response to HSV antigen was diminished in infected infants compared with adults with primary HSV infection. IFN-a may have a direct antiviral effect and also induces natural killer cell activity, a nonspecific immune mechanism that is potentially important in the early host response to primary HSV infection. Diminished or absent IFN-y production by HSV-stimulated mononuclear cells from normal and HSV-infected neonates in the first month of life has also been described [15, 21] . In contrast to the situation in infants with perinatally acquired HSV infection, immunologic evaluation of infants with intrauterine HSV infection showed high levels of NAb within the first few days of life and early detection of T lymphocyte proliferation in response to HSV. These infants characteristically had severe recurrent mucocutaneous infection in the first year of life but did not develop lifethreatening dissemination, albeit all had severe sequelae from the intrauterine infection.
Antiviral therapy for neonatal HSV infection influenced the immune response to HSV, as has been observed among adults treated with ACV. Neonates treated with vidarabine were more likely to have a NAb titer of >1 :20 by three to four weeks after onset and were more likely to show a fourfold rise in titer of NAb than were ACV recipients. Adults with primary genital HSV infection who were given ACV had a lower mean NAb response and delayed or lessfrequent development of antibodies to three HSVspecific polypeptides compared with placebo recipients [22] . A higher percentage of infants treated with vidarabine (50070) also had a TI of~3.0 compared with ACV recipients (14070). Adults with primary genital HSV infections treated with systemic ACV had delayed peak lymphocyte proliferation relative to placebo controls [23] . Bone marrow transplant recipients with mucocutaneous HSV infections treated with ACV had earlier and more severe HSV recurrences after discontinuation of ACV administration than did patients receiving placebo [24] . Despite the immunologic differences there was no apparent difference clinically between infants treated with ACV and those given vidarabine. The occurrence of encephalitis in two infants previously treated with ACV and in no infants treated with vidarabine probably reflects the fact that more infants received ACV than vidarabine. Clinically, these two agents Sullender et al. have equivalent efficacy [25] . The effect of ACV on HSV immunity does not diminish the value of the drug for treatment of neonatal HSV infection. However, the delayed development of HSV immunity in infants and the possibility of life-threatening recurrences suggest the need for immunomodulating or suppressive antiviral therapy after the initial treatment of some infants infected with HSV.
